Equillium, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Equillium is a clinical-stage biotechnology company developing treatments for immune-inflammatory diseases. It has no approved products and has generated no revenue.
Financial results and liquidity
| Metric | Q2 2022 | Six months 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $9.5 million | $20.3 million | $6.0 million; $11.9 million |
| Acquired in-process R&D expense | None | $23.0 million | None |
| General and administrative expense | $4.1 million | $7.6 million | $2.9 million; $5.7 million |
| Net loss | $14.1 million | $51.5 million | $9.2 million; $18.1 million |
| Net loss per share, basic and diluted | $0.41 | $1.56 | $0.31; $0.64 |
At June 30, cash and cash equivalents were $23.8 million and short-term investments were $33.8 million, totaling $57.6 million. Current assets were $60.5 million against current liabilities of $15.2 million. Operating cash used in the first half was $23.4 million, compared with $14.9 million in 2021. The filing does not provide a meaningful product gross margin; the company has no product revenue.
Total notes payable were approximately $10.3 million, including $4.3 million current and $6.0 million long-term. The loan matures June 2024; interest-only payments were extended through September 30, 2022, after which scheduled principal payments resume. The company reported compliance with loan covenants at June 30.
Material changes and notable items
- Q2 R&D expense increased $3.5 million year over year, principally due to startup costs for the pivotal EQUATOR aGVHD trial, additional nonclinical work, and higher staffing. First-half R&D increased $8.4 million.
- First-half results include a $23.0 million acquired in-process R&D charge for the February 2022 Bioniz asset acquisition. The charge reflects acquired candidates with no alternative future use and is noncash.
- Equillium acquired EQ101, EQ102, and a product-discovery platform. It issued 4.82 million shares at closing and may issue up to about 879,000 additional shares subject to adjustments. The merger agreement also provides for contingent payments of up to $57.5 million for regulatory events and up to $250 million for commercialization events tied to EQ101.
- Outstanding common shares rose to 34.35 million from 29.46 million at year-end 2021, primarily reflecting shares issued for Bioniz. The filing also reports 5.30 million options and 1.37 million warrants outstanding; potential dilution warrants attention.
Outlook, management commentary, and risks
- Management expects available cash, cash equivalents, and investments, together with proceeds that could be raised at the company’s discretion under its committed Lincoln Park equity line, to fund operations for at least 12 months from the filing date. This estimate depends on assumptions; the company expects to need additional capital to complete development and commercialization.
- Management expects expenses and losses to increase as it advances its programs. It planned to initiate a Phase 2 EQ101 alopecia areata study and a Phase 1 EQ102 study in the second half of 2022. EQUATOR, a pivotal Phase 3 trial of itolizumab in aGVHD, began in March 2022. Interim lupus nephritis data were planned for mid-2022.
- Equillium prioritized aGVHD and lupus/lupus nephritis development for itolizumab; it completed the asthma study in 2021 and was reassessing future asthma development. COVID-19-related disruptions had affected trial enrollment and could continue to affect trials, supply, and operations.
- Key risks include clinical-trial delay or failure, uncertain regulatory approval and commercialization, financing needs and potential dilution, dependence on contract manufacturers and CROs, reliance on Biocon-licensed rights and itolizumab supply, intellectual-property risks, and competition. The company also cites geopolitical and capital-market uncertainty related to the conflict in Ukraine.
- The company reported no legal proceedings. Management concluded disclosure controls were effective at a reasonable-assurance level as of June 30, 2022, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the stated cash runway remains adequate as clinical spending rises, and what financing terms or dilution may be required.
- Progress, enrollment, safety, and data quality for EQUATOR and the lupus nephritis program, as well as initiation and progress of planned EQ101 and EQ102 trials.
- Manufacturing continuity and supply arrangements, particularly Equillium’s dependence on Biocon for itolizumab and foreign clinical supply.
- The timing and potential financial impact of Bioniz contingent payments and any remaining share issuance adjustments.
- Debt repayment timing after the interest-only period, covenant compliance, and availability of the Lincoln Park equity line.